KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Revenue (2016 - 2026)

Biogen has reported Revenue over the past 18 years, most recently at $2.5 billion for Q1 2026.

  • For Q1 2026, Revenue rose 1.93% year-over-year to $2.5 billion; the TTM value through Mar 2026 reached $9.9 billion, up 1.23%, while the annual FY2025 figure was $9.9 billion, 2.22% up from the prior year.
  • Revenue for Q1 2026 was $2.5 billion at Biogen, up from $2.3 billion in the prior quarter.
  • Over five years, Revenue peaked at $2.6 billion in Q2 2025 and troughed at $2.3 billion in Q4 2025.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: fell 9.73% in 2022 and later grew 7.33% in 2025.
  • Year by year, Revenue stood at $2.5 billion in 2022, then decreased by 6.2% to $2.4 billion in 2023, then rose by 2.87% to $2.5 billion in 2024, then dropped by 7.14% to $2.3 billion in 2025, then increased by 8.7% to $2.5 billion in 2026.
  • Business Quant data shows Revenue for BIIB at $2.5 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.5 billion in Q3 2025.